General Anxiety Disorder - Pipeline Review, H2 2014

Published: Nov, 2014 | Pages: 40 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

General Anxiety Disorder - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'General Anxiety Disorder - Pipeline Review, H2 2014', provides an overview of the General Anxiety Disorder's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for General Anxiety Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for General Anxiety Disorder and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of General Anxiety Disorder
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for General Anxiety Disorder and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the General Anxiety Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the General Anxiety Disorder pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for General Anxiety Disorder
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding General Anxiety Disorder pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
General Anxiety Disorder Overview 6
Therapeutics Development 7
Pipeline Products for General Anxiety Disorder - Overview 7
Pipeline Products for General Anxiety Disorder - Comparative Analysis 8
General Anxiety Disorder - Therapeutics under Development by Companies 9
General Anxiety Disorder - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Unknown Stage Products 12
General Anxiety Disorder - Products under Development by Companies 13
General Anxiety Disorder - Companies Involved in Therapeutics Development 14
Edgemont Pharmaceuticals, LLC 14
H. Lundbeck A/S 15
Rottapharm SpA 16
General Anxiety Disorder - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 23
Drug Profiles 24
EDG-004 - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
EDG-008 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
itriglumide - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Small Molecule to Modulate Glutamate Receptor for Anxiety Disorders - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
tedatioxetine - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
vortioxetine hydrobromide - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
General Anxiety Disorder - Recent Pipeline Updates 33
General Anxiety Disorder - Dormant Projects 37
General Anxiety Disorder - Discontinued Products 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40

List of Tables
Number of Products under Development for General Anxiety Disorder, H2 2014 7
Number of Products under Development for General Anxiety Disorder - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Late Stage Development, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Unknown Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
General Anxiety Disorder - Pipeline by Edgemont Pharmaceuticals, LLC, H2 2014 14
General Anxiety Disorder - Pipeline by H. Lundbeck A/S, H2 2014 15
General Anxiety Disorder - Pipeline by Rottapharm SpA, H2 2014 16
Assessment by Monotherapy Products, H2 2014 17
Number of Products by Stage and Target, H2 2014 19
Number of Products by Stage and Mechanism of Action, H2 2014 21
Number of Products by Stage and Route of Administration, H2 2014 22
Number of Products by Stage and Molecule Type, H2 2014 23
General Anxiety Disorder Therapeutics - Recent Pipeline Updates, H2 2014 33
General Anxiety Disorder - Dormant Projects, H2 2014 37
General Anxiety Disorder - Discontinued Products, H2 2014 38